[go: up one dir, main page]

MX2021008979A - Peptidos terapeuticos. - Google Patents

Peptidos terapeuticos.

Info

Publication number
MX2021008979A
MX2021008979A MX2021008979A MX2021008979A MX2021008979A MX 2021008979 A MX2021008979 A MX 2021008979A MX 2021008979 A MX2021008979 A MX 2021008979A MX 2021008979 A MX2021008979 A MX 2021008979A MX 2021008979 A MX2021008979 A MX 2021008979A
Authority
MX
Mexico
Prior art keywords
cell
disclosed
mechanisms controlling
proliferation
cellular mechanisms
Prior art date
Application number
MX2021008979A
Other languages
English (en)
Inventor
Kenneth Cundy
Original Assignee
Cohbar Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cohbar Inc filed Critical Cohbar Inc
Publication of MX2021008979A publication Critical patent/MX2021008979A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Las descripciones en la presente se refieren a los campos de la biología celular y la modulación de los mecanismos celulares que controlan la viabilidad celular, la proliferación celular y los procesos metabólicos. Más específicamente se describen en la presente péptidos eficaces para modular los mecanismos celulares que controlan la viabilidad celular, la proliferación celular y los procesos metabólicos, incluida la señalización celular asociada con la proliferación celular aberrante y la malignidad. También se describen en la presente péptidos eficaces para modulares mecanismos celulares que controlan la viabilidad celular, el tratamiento de enfermedades metabólicas y como agentes citoprotectores. También se describen péptidos eficaces en el tratamiento de la fibrosis.
MX2021008979A 2019-01-28 2020-01-28 Peptidos terapeuticos. MX2021008979A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962797701P 2019-01-28 2019-01-28
PCT/US2020/015431 WO2020160003A1 (en) 2019-01-28 2020-01-28 Therapeutic peptides

Publications (1)

Publication Number Publication Date
MX2021008979A true MX2021008979A (es) 2021-11-12

Family

ID=69740611

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021008979A MX2021008979A (es) 2019-01-28 2020-01-28 Peptidos terapeuticos.

Country Status (11)

Country Link
US (1) US20220226484A1 (es)
EP (1) EP3917944A1 (es)
JP (1) JP2022518814A (es)
KR (1) KR20210121132A (es)
CN (1) CN113518784A (es)
AU (1) AU2020216135A1 (es)
CA (1) CA3127336A1 (es)
IL (1) IL285144A (es)
MX (1) MX2021008979A (es)
SG (1) SG11202107761SA (es)
WO (1) WO2020160003A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102709142B1 (ko) * 2020-08-27 2024-09-26 에이치엘비사이언스 주식회사 알츠하이머 치매 예방 또는 치료용 펩타이드 조성물
WO2022087224A1 (en) * 2020-10-21 2022-04-28 Cohbar, Inc. Method of treating fibrosis with a combination therapy
CN116554267A (zh) * 2022-01-30 2023-08-08 江苏众红生物工程创药研究院有限公司 聚乙二醇修饰的激肽或其变体和药物应用
KR20250068882A (ko) * 2023-11-10 2025-05-19 (주) 넥셀 특발성 폐섬유증 예방 또는 치료용 건조 분말 흡입 제형 및 이의 제조방법

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
US5846528A (en) 1996-01-18 1998-12-08 Avigen, Inc. Treating anemia using recombinant adeno-associated virus virions comprising an EPO DNA sequence
US5858351A (en) 1996-01-18 1999-01-12 Avigen, Inc. Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors
US6015709A (en) 1997-08-26 2000-01-18 Ariad Pharmaceuticals, Inc. Transcriptional activators, and compositions and uses related thereto
ATE280590T1 (de) 2000-05-23 2004-11-15 Neurologix Inc Glutaminsäure decarboxylase (gad) abgabesystem zur behandlung neurodegeneraliver erkrankungen
US6835713B2 (en) * 2001-02-16 2004-12-28 University Of Pittsburgh Virus derived antimicrobial peptides
US7588757B2 (en) 2001-03-14 2009-09-15 Genzyme Corporation Methods of treating Parkinson's disease using recombinant adeno-associated virus virions
WO2002086122A2 (en) * 2001-03-14 2002-10-31 Hybrigenics Protein-protein interactions in adipocytes
WO2003052052A2 (en) 2001-12-17 2003-06-26 The Trustees Of The University Of Pennsylvania Adeno-associated virus (aav) serotype 9 sequences, vectors containing same, and uses therefor
US20070015238A1 (en) 2002-06-05 2007-01-18 Snyder Richard O Production of pseudotyped recombinant AAV virions
AU2004204494B2 (en) 2003-01-09 2011-09-29 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US20040258666A1 (en) 2003-05-01 2004-12-23 Passini Marco A. Gene therapy for neurometabolic disorders
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
WO2006119432A2 (en) 2005-04-29 2006-11-09 The Government Of The U.S.A., As Rep. By The Sec., Dept. Of Health & Human Services Isolation, cloning and characterization of new adeno-associated virus (aav) serotypes
EP1857552A1 (en) 2006-05-20 2007-11-21 Cargill Incorporated Thermostable xylose isomerase enzyme
US7846445B2 (en) 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
HUE041928T2 (hu) 2006-02-08 2019-06-28 Genzyme Corp Génterápia A-típusú Niemann-Pick-betegségre
WO2007120542A2 (en) 2006-03-30 2007-10-25 The Board Of Trustees Of The Leland Stanford Junior University Aav capsid library and aav capsid proteins
US8292769B2 (en) 2006-11-22 2012-10-23 Lawson Jr Thomas Towles Transmission
CN103298935A (zh) 2007-08-15 2013-09-11 阿穆尼克斯公司 用于改善生物活性多肽性能的组合物和方法
US9217155B2 (en) 2008-05-28 2015-12-22 University Of Massachusetts Isolation of novel AAV'S and uses thereof
SG172291A1 (en) 2008-12-19 2011-07-28 Univ Indiana Res & Tech Corp Amide based glucagon superfamily peptide prodrugs
SG10201502270TA (en) 2010-03-29 2015-05-28 Univ Pennsylvania Pharmacologically induced transgene ablation system
EP3536781A1 (en) 2010-04-23 2019-09-11 University of Massachusetts Cns targeting aav vectors and methods of use thereof
CN103189507A (zh) 2010-10-27 2013-07-03 学校法人自治医科大学 用于向神经系统细胞导入基因的腺相关病毒粒子
US8865881B2 (en) 2011-02-22 2014-10-21 California Institute Of Technology Delivery of proteins using adeno-associated virus (AAV) vectors
US20160058881A1 (en) 2013-03-15 2016-03-03 Indiana University Research And Technology Corporation Prodrugs with prolonged action
CN105229023B (zh) * 2013-03-15 2019-08-16 加利福尼亚大学董事会 源自线粒体的肽mots3调节代谢和细胞存活
BR112015028605A8 (pt) 2013-05-15 2019-12-24 Univ Minnesota uso de uma composição e uso de um imunossupressor e uma composição
ES2739288T3 (es) 2013-09-13 2020-01-30 California Inst Of Techn Recuperación selectiva
PL3137497T5 (pl) 2014-05-02 2025-06-09 Genzyme Corporation Wektory AAV do terapii genowej siatkówki i OUN
MX2017005834A (es) 2014-11-05 2017-11-17 Voyager Therapeutics Inc Polinucleotidos aad para el tratamiento de la enfermedad de parkinson.
MA41451A (fr) 2015-02-04 2017-12-12 Univ Washington Constructions anti-tau
MX2018015869A (es) * 2016-06-24 2019-08-12 Univ Southern California Analogos de peptido derivado mitocondrial codificado en la subunidad nd-dos de humanos como agentes terapeuticos para diabetes, obesidad y sus enfermedades y complicaciones asociadas.
EP3519431A1 (en) * 2016-09-28 2019-08-07 Cohbar Inc. Therapeutic mots-c related peptides

Also Published As

Publication number Publication date
US20220226484A1 (en) 2022-07-21
CA3127336A1 (en) 2020-08-06
IL285144A (en) 2021-09-30
WO2020160003A1 (en) 2020-08-06
KR20210121132A (ko) 2021-10-07
SG11202107761SA (en) 2021-08-30
EP3917944A1 (en) 2021-12-08
JP2022518814A (ja) 2022-03-16
AU2020216135A1 (en) 2021-08-05
CN113518784A (zh) 2021-10-19

Similar Documents

Publication Publication Date Title
MX2022001927A (es) Peptidos terapeuticos.
MX2021008979A (es) Peptidos terapeuticos.
Theocharis et al. Insights into the key roles of proteoglycans in breast cancer biology and translational medicine
SA521421744B1 (ar) علاج مناعي توليفي للسرطان
PH12019502870A1 (en) Small molecule modulators of human sting
MX2024013525A (es) Metodos para tratar canceres y potenciar la eficacia de agentes terapeuticos para el redireccionamiento de celulas t
PH12018502429A1 (en) Antibody molecules for cancer treatment
MX2020005463A (es) Anticuerpos anti grupo de diferenciacion 47 (anti-cd47) y sus usos para tratar cancer.
MX2018007840A (es) Materiales y metodos para el tratamiento de la esclerosis lateral amiotrofica y/o la degeneracion lobar frontotemporal.
WO2019094642A8 (en) T cell manufacturing compositions and methods
PH12020551427A1 (en) Epinephrine spray formulations
EP4484443A3 (en) Materials and methods for treatment of friedreich ataxia and other related disorders
NZ759034A (en) Viral vectors encoding recombinant fix with increased expression for gene therapy of hemophilia b
GB2535937A (en) Methods and compositions for modulating the immune system with Arginase I
EP4292606A3 (en) Compositions for treating cancer
WO2019166412A9 (en) Modulation of pla2-g1b in therapy
WO2016004906A3 (zh) 一种肿瘤血管阻断剂多肽、基因、表达载体及其应用
WO2020000035A8 (en) Modified t cells and uses thereof
MX2023011035A (es) Composición de terapia génica y tratamiento de la miocardiopatía arritmogénica del ventriculo derecho.
MX2019013210A (es) Factores de crecimiento recombinantes modificados de fibroblastos y usos terapéuticos de los mismos.
MX2023004942A (es) Compuestos biciclicos y usos de los mismos para el tratamiento de enfermedades.
PH12022551035A1 (en) Siglec-9 ecd fusion molecules and methods of use thereof
WO2021081457A3 (en) Methods and agents for enhancing t cell therapies
PH12019502721A1 (en) Botulinum neurotoxin for treatment of disorders associated with melanocyte hyperactivity and/or excess melanin
MX2025001358A (es) Composiciones y métodos para inducir ferroptosis